New P-glycoprotein inhibitors: potential tools to reduce Multidrug Resistance by VANNI, MICHAEL
  





School of Graduate Studies 












“New P-glycoprotein inhibitors: potential tools to 









DIRECTOR OF THE SCHOOL 













1.  Introduction                                                                                                           6          
 
1.1.  Multidrug Resistance                                                                                                                   6 
 
1.2.  Multidrug Resistance to Anticancer Drugs (neoplastic resistance)                                             8 
 
1.3.  Efflux transporters                                                                                                                     10 
 
1.4.  ATP-binding cassette (ABC)                                                                                                     12 
1.4.1.  ABC transporter architecture                                                                                       16 
        1.4.2.  Transport mechanism                                                                                                    20 
 
1.5.  Characterstics of the MRP1 and MRP2 Transporters                                                                21 
  
1.6.  Breast cancer resistance protein (BCRP)                                                                                   24 
        1.6.1.  Structure and cellular localization                                                                                  25 
        1.6.2.  Transport properties                                                                                                        26 
      1.6.3.  Dimer formation                                                                                                               27 
 
1.7.  P-glycoprotein (P-gp)                                                                                                                 27 
        1.7.1.  P-gp at the level of blood-brain barrier (BBB)                                                               31 
     1.7.2.  P-gp at the level of placenta                                                                                           34 
1.7.3.  Potential role of P-gp and MRP1 at the blood-cerebrospinal fluid barrier                   37 
 
1.8.  Identification of P-gp binding regions and pockets                                                                    40 
 
1.9.  The transport cycle of P-glycoprotein                                                                                        45 
 
1.10.  Expression of P-Glycoprotein in Human Tumors                                                                    49 
 
1.11.  Intentional modulation of the function of P-Glycoprotein                                                       51 
 
1.12.  Candidate sites for putative P-glycoprotein inhibitors                                                             54 
 
Bibliography                                                                                                                                       58 
 
 
2.  Multidrug Resistance Reverting Agents and P-gp modulators                              68 
 
2.1.  Pharmacological control of MDR                                                                                              68 
 
2.2.  Theorical SAR studies to predict MDR modulating activity                                                     69 
 
2.3.  Transported Substrates of P-gp                                                                                                  72 
 
2.4.  P-glycoprotein inhibitor development                                                                                        73 
        2.4.1.  First generation inhibitors                                                                                              73 
        2.4.2.  Second generation inhibitors                                                                                           76  
        2.4.3.  Third generation inhibitors                                                                                             77 
  
2.5.  Structure-Activity Relationship among P-glycoprotein Modulators                                          78 
        2.5.1.  Verapamil-related compounds                                                                                        78 
        2.5.2.  Nimodipine-related compounds                                                                                       80 
        2.5.3.  Quinine-related compounds                                                                                            82 
        2.5.4.  Dipyridamole-related compounds                                                                                   84 
        2.5.5.  Cyclosporin A-related compounds                                                                                  86   
        2.5.6.  Taxanes                                                                                                                            87  
2.5.7.  Trifluoperazine-related compounds                                                                                88  
        2.5.8.  Propafenone-related compounds                                                                                     89   
       2.5.9.  Amiodarone-related compounds                                                                                     90 
        2.5.10.  Flavonoid-related compounds                                                                                       91 
        2.5.11.  Alkaloids                                                                                                                        92 
       2.5.12.  Terpenes                                                                                                                        93  
        2.5.13.  Steroid-related compounds                                                                                            94  
        2.8.14.  Oligonucleotides                                                                                                            95 
 
2.6.  Phamacophore Modeling                                                                                                            96 
 
2.7.  Third generation P-gp inhibitors                                                                                                99 
        2.7.1.  Valspodar                                                                                                                        99 
        2.7.2.   Zosuquidar                                                                                                                      99 
        2.7.3.  Tariquidar                                                                                                                        99 
        2.7.4.  Biricodar                                                                                                                          99 
        2.7.5.  Elacridar                                                                                                                        100 
        2.7.6.  Timcodar                                                                                                                        100 
       2.7.7.  Laniquidar                                                                                                                      100 
       
 Bibliography                                                                                                                                    103 
 
 
3.  New P-Glycoprotein inhibitors and their screening: Potential tools to reduce 
Multidrug Resistance                                                                                              117 
3.1.  Introduction                                                                                                                              117 
 
3.2.  Current State of Art                                                                                                                  119 
 
3.3.  Aim of the thesis                                                                                                                       125 
 
3.4.  Substitution of the Arylmethyl portion linked to the PEP (or 3-methoxy PEP) nucleus         127 
      3.4.1.  Synthesis                                                                                                                          128 
 3.4.2.  Results and discussion                                                                                                    131 
 
3.5.  Effect of methoxylation on B- and/or C- rings                                                                         135  
        3.5.1.  Synthesis                                                                                                                        137 
        3.5.1.  Results and discussion                                                                                                   141 
 
3.6.  Substitution of the ethyl chain with a methylenoxy linker                                                       145                                                       
        3.6.1.  Synthesis                                                                                                                        145 
 
3.7.  Bioisoster substitution of oxygen atom with a nitrogen one                                                    147 
       3.7.1.  Synthesis                                                                                                                         149 
       3.7.2.  Results and discussion                                                                                                    155 
 
3.8.  Replacement of amino function with an amido one                                                                 158 
        3.8.1.  Synthesis                                                                                                                        159 
 
3.9.  Replacement of B-ring with basic nucleuses                                                                            160 
        3.9.1.  Synthesis                                                                                                                        162 
        3.9.2.  Results and discussion                                                                                                   164 
 
3.10.  Further piperazine-nucleus                                                                                                     173 
          3.10.1.  Synthesis                                                                                                                    174 
 
 Bibliography                                                                                                                                     176 
 
 
4.  Experimental section                                                                                          177 
 
4.1.  General Methods                                                                                                                    177 
    4.1.1.  Elemental Analysis                                                                                                        221 
 
4.2.  Biological Methods                                                                                                                  223                                                                                                                
  4.2.1.  Cell lines                                                                                                                        223 
  4.2.2.  Permeability Experiments. Preparation of Caco-2 Monolayer                                    224  
4.2.3.  Drug Transport Experiment                                                                                          224 
  4.2.4.  Cell ATP Availability Assay                                                                                          225 
  4.2.5.  [3H] Substrate Transport Inhibition                                                                              225  
  4.2.6.  [3H] Mithoxantrone Transport Inhibition                                                                     226 
  4.2.7.  Calcein-AM Assay in MDCK-P-gp Cells                                                                      227 
  4.2.8.  Radioligand Binding Assay at Rat Human Cloned 5-HT1A Receptor                            228  
 4.2.10.  Statistical Analysis                                                                                                       228 
Bibliography                                                                                                                                     230 
 
